Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.
about
Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepamClinically and pharmacologically relevant interactions of antidiabetic drugsCase studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesBDDCS applied to over 900 drugs.Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsPopulation pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake.Influence of dietary substances on intestinal drug metabolism and transport.Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase.Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsOral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectivesOn the assessment of effects of food on the pharmacokinetics of drugs in early development.A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.The effect of food components on the absorption of P-gp substrates: a review.A review and assessment of potential sources of ethnic differences in drug responsiveness.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine.Challenges and opportunities in achieving bioequivalence for fixed-dose combination products.The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.Drug-drug interactions of antifungal agents and implications for patient care.Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.Food Inhibits the Oral Bioavailability of the Major Green Tea Antioxidant Epigallocatechin Gallate in Humans.Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteersPredicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effectsCurrent methods for predicting human food effect.Individual differences in timing of peak positive subjective responses to d-amphetamine: Relationship to pharmacokinetics and physiologyIs it appropriate regarding patient preference to take Myrtol standardized enteric-coated soft capsules after a meal rather than at fasted state? A food-drug pharmacokinetic interaction study in healthy Chinese volunteers.Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjectsMechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake.Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect.From bench to humans: formulation development of a poorly water soluble drug to mitigate food effectThe role of diet on the clinical pharmacology of oral antineoplastic agents.Inorganic matrices: an answer to low drug solubility problem.
P2860
Q24679467-6C4392BA-681D-4BB9-B415-3F75D54B3991Q26752468-D3417BAB-6CB6-4F0B-95ED-D986E76F6386Q30576914-0117E74E-1859-4F65-BD90-214EE045FC2CQ30662113-989747C9-C790-40AC-9AFA-67120FBA2A22Q33683206-4462BA3E-4177-41C5-99BD-D9973966CA06Q34206152-B4CFBCD5-1CEF-4EFC-AC9D-4F7FF1418220Q34285711-B664E681-5ED8-4455-A508-E36A9C267F1DQ34328266-DEF831D5-6483-4A89-A95E-79073A38B618Q34553835-EC448C2B-95BC-4E70-886E-1CD3BE12915AQ34561741-6CC38135-2E69-49EA-A037-B7316E7CE5A8Q34582069-2F24DD5B-6785-48AE-9E50-9FB77E0E35ACQ34584089-B7C6C4AD-144E-45B5-A253-88EA90C8BE68Q34632445-274D5D77-5E18-4835-861E-AC94798566D4Q34642102-04344773-E856-4666-B01F-8CFF19E8CA3FQ34665881-2233DFC4-9949-49BC-A98D-617E98E726FAQ34680655-B78F52DF-19F7-475A-BD5B-939DD5C54B24Q35083696-BB9B5F97-8F6B-4DED-B472-AB6386A9191FQ35217493-BAF27F9B-00DD-4E67-A170-47359B8956DEQ35876954-0701A442-C921-4856-8C06-FEC7ABD977E4Q35891741-5F77BF2E-6241-418A-AEB1-8FB790C555ACQ36065586-096AC575-DF52-4AD9-9499-12DFDE834894Q36088451-81CFE557-498F-4900-901A-CB19C7DB6AD9Q36283721-7FFFB147-3EE6-4003-9417-6D0DD6C88EB2Q36303746-3FCB858F-C1F0-4532-B13D-D020A62B397DQ36335008-3775D309-F694-4A80-B3FB-264E4C48C77DQ36396203-7A4399BA-2B3B-47AA-B3DD-CA384779B890Q36467274-AE89AEE7-CE58-4FF0-BDF8-AD296F92310BQ36648773-3936AAF5-6C78-4362-839C-16EFE2B9BDA0Q36922216-E6A5EE93-76F4-4FD3-93B8-D81FF0CDC22CQ37058658-782E433A-27F4-49DC-BEF8-2E7F38A51189Q37149095-65B926DA-38D1-45F0-B02D-01070CCE4A2AQ37171894-B9DFEF3A-94F0-46E2-8EEB-500019ACB915Q37309160-B1D157AF-7667-47BF-AC9C-477918DCD8AFQ37320807-07E96932-E3A3-4302-A803-F8EB3C03FD59Q37427926-D86AE5CD-733C-4451-83BD-65814B805821Q37540015-96D98A45-B5D5-4C85-8CB2-A6F5A383150DQ37671837-D3137AAB-55FC-4DCF-A8E6-C8DEDB70D575Q37671854-F88AF25D-23B2-476D-8BBA-1DC95CB6EAAEQ37907103-9FC30ADA-7AA2-4ECD-BB77-FD6A34E6BF3CQ38051672-354ED0F8-76AE-4127-8E6B-B5F9A1BA1291
P2860
Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Drug, meal and formulation int ...... ration. Clinical implications.
@ast
Drug, meal and formulation int ...... ration. Clinical implications.
@en
type
label
Drug, meal and formulation int ...... ration. Clinical implications.
@ast
Drug, meal and formulation int ...... ration. Clinical implications.
@en
prefLabel
Drug, meal and formulation int ...... ration. Clinical implications.
@ast
Drug, meal and formulation int ...... ration. Clinical implications.
@en
P2093
P1476
Drug, meal and formulation int ...... ration. Clinical implications.
@en
P2093
P304
P356
10.2165/00003088-199936030-00004
P577
1999-03-01T00:00:00Z
P6179
1031175551